Am J Hematol

• 

  Publication Venue For

  • Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH..  96:E5-E8. 2021
  • Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials..  96:E11-E15. 2021
  • Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium..  95:1066-1074. 2020
  • Real-world effectiveness of eliglustat in treatment-naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry..  95:1038-1046. 2020
  • Isolated cerebrospinal fluid relapse of acute myeloid leukemia status post stem cell transplant: A neuroleukemiosis manifesting as polyneuropathy..  95:1001-1002. 2020
  • Characterization of the severe phenotype of pyruvate kinase deficiency. 2020
  • Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects..  95:662-671. 2020
  • Hematologic findings in a large sample of patients with anorexia nervosa and bulimia nervosa..  95:E98-E101. 2020
  • Third trimester and early postpartum period of pregnancy have the greatest risk for ACS in women with SCD..  94:E328-E331. 2019
  • Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes..  94:741-750. 2019
  • Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors..  94:563-574. 2019
  • A multi-institutional comparison of younger and older adults with sickle cell disease..  94:E115-E117. 2019
  • Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low-resource setting..  94:223-230. 2019
  • Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial..  94:21-28. 2019
  • Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease..  93:1451-1460. 2018
  • The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease..  93:E391-E395. 2018
  • A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients..  93:E362-E365. 2018
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial..  93:1394-1401. 2018
  • A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting..  93:E167-E170. 2018
  • Physician decision making in selection of second-line treatments in immune thrombocytopenia in children..  93:882-888. 2018
  • A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD)..  93:159-168. 2018
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia..  93:E49-E52. 2018
  • Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low-resource setting..  92:872-878. 2017
  • Recognition of early mortality in multiple myeloma by a prediction matrix..  92:915-923. 2017
  • Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry..  92:929-939. 2017
  • Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia..  92:730-738. 2017
  • Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia..  92:E31-E34. 2017
  • Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy..  91:1002-1007. 2016
  • Patent foramen ovale in adults with sickle cell disease and stroke..  91:E358-E360. 2016
  • "Hairy" cells in acute promyelocytic leukemia: Excess myeloperoxidase with formation of needle-shaped crystalline projections on the cytochemical stain in a case with variant morphology..  91:747-748. 2016
  • Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study..  91:687-691. 2016
  • Secondhand smoke is associated with more frequent hospitalizations in children with sickle cell disease..  91:313-317. 2016
  • Effects of hydroxyurea treatment for patients with hemoglobin SC disease..  91:238-242. 2016
  • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials..  91:199-204. 2016
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy..  90:796-799. 2015
  • Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma..  90:E111-E116. 2015
  • Evidence gaps in the management of sickle cell disease: A summary of needed research..  90:273-275. 2015
  • Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry..  90:187-192. 2015
  • Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission..  90:242-249. 2015
  • Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy..  90:139-143. 2015
  • Silent cerebral infarction, income, and grade retention among students with sickle cell anemia..  89:E188-E192. 2014
  • Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia..  89:721-725. 2014
  • Factors associated with survival in a contemporary adult sickle cell disease cohort..  89:530-535. 2014
  • Parent education and biologic factors influence on cognition in sickle cell anemia..  89:162-167. 2014
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial..  88:932-938. 2013
  • Recent advances in de novo CD5+ diffuse large B cell lymphoma..  88:798-802. 2013
  • Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease..  88:179-184. 2013
  • Pathological bone fractures in a 20-year old athletic male with multifocal solitary plasmacytoma of bone..  87:626-627. 2012
  • Antiphospholipid syndrome: laboratory testing and diagnostic strategies..  87 Suppl 1:S75-S81. 2012
  • Determination of human platelet antigen typing by molecular methods: Importance in diagnosis and early treatment of neonatal alloimmune thrombocytopenia..  87:525-528. 2012
  • Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors..  87 Suppl 1:S141-S145. 2012
  • Postpartum hemorrhage: when uterotonics and sutures fail..  87 Suppl 1:S16-S22. 2012
  • Complications of implantable venous access devices in patients with sickle cell disease..  87:224-226. 2012
  • Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes..  86:E70-E73. 2011
  • Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma..  86:627-630. 2011
  • An unusual nodal marginal zone lymphoma with bright CD10 expression: a potential diagnostic pitfall..  85:546-548. 2010
  • Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study..  85:467-471. 2010
  • IgG-lambda plasma cell myeloma with cytoplasmic azurophilic inclusion bodies..  85:516-517. 2010
  • Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians..  85:528-532. 2010
  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up..  85:403-408. 2010
  • Prominent Dutcher body formation in a case of follicular lymphoma with BCL6 gene rearrangement and intact BCL2 gene..  85:218-219. 2010
  • Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease..  85:36-40. 2010
  • Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement..  85:79-81. 2010
  • Definitions of the phenotypic manifestations of sickle cell disease..  85:6-13. 2010
  • Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study..  85:29-35. 2010
  • Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures..  84:703-709. 2009
  • Langerhans cell histiocytosis following acute leukemia in an adult..  84:693-694. 2009
  • The excess burden of stroke in hospitalized adults with sickle cell disease..  84:548-552. 2009
  • Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience..  84:408-413. 2009
  • Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines..  84:366-370. 2009
  • D-dimer for the diagnosis of venous thromboembolism in children..  84:62-63. 2009